A World-Class API and FDF Manufacturer

Dedicated manufacturing operations were established in 1986 as Nanjing King-friend Biochemical Pharmaceutical Company (NKF).

Today NKF:

  • Generates 15-20% of the global supply of Heparin
  • Produces prefilled syringes and vials in 2 facilities that are:
    • State-of-the-art with fully integrated isolator systems
    • Located in Nanjing and Chengdu, China
    • U.S. FDA approved
  • Employs more than 500 personnel, including 100 R&D experts
  • Cytotoxic and non-cytotoxic
  • Vial (liquid, lyophilized)
  • API plant
    • Heparin and LMWH
  • FDF plant
    • Prefilled syringe
    • Vial (liquid, lyophilized)
Stock Exchange

Publically listed on Shanghai Stock Exchange with market capitalization of $3 billion U.S.

Stock Exchange

CRO/CMO partner to global pharmaceutical companies

Stock Exchange

Produces 100 million syringes and 70 million vials annually